# COVID-19’s disruptions to cancer care pathways and widening of health inequalities in the UK: a systematic review

**Authors:** Cheuk Him Michael Lam, Kar Chun Cheung, Thomas Mason, Bruce Hollingsworth

PMC · DOI: 10.1186/s12913-026-14313-8 · BMC Health Services Research · 2026-03-26

## TL;DR

This review shows how the COVID-19 pandemic worsened cancer care inequalities in the UK, especially for people in poor areas, ethnic minorities, and the elderly.

## Contribution

The study provides the first comprehensive synthesis of how pandemic disruptions widened cancer care disparities in the UK.

## Key findings

- Socioeconomic status strongly influenced access to cancer screening and treatment during the pandemic.
- Ethnic minorities, especially Black patients, faced significant reductions in hospital admissions and screening participation.
- Older adults maintained higher screening rates but faced greater risks from both cancer and COVID-19.

## Abstract

The COVID-19 pandemic has significantly impacted cancer care services in the United Kingdom (UK), potentially exacerbating pre-existing health inequalities. While emerging studies have documented service disruptions, a comprehensive synthesis of how these disruptions have widened disparities remains absent. This systematic review examines the extent to which the pandemic disrupted the cancer care pathway and intensified existing disparities across the UK, identifying key sociodemographic and geographical factors influencing access to services.

A systematic search of PubMed, Scopus, and CINAHL was conducted for studies published between January 2020 and October 2024. Eligible studies included observational and empirical research examining disparities in cancer screening, diagnosis, treatment, and outcomes during the COVID-19 pandemic, as well as the corresponding mitigation strategies. Data extraction followed a structured approach using a custom-developed extraction form designed for this review. Study quality was appraised using a bespoke scoring system, classifying studies as high, moderate, or low importance. Narrative synthesis, following the framework outlined by Popay et al., was then employed to identify key themes and explore relationships between findings.

30 out of 457 studies met the inclusion criteria. The review found that socioeconomic status (SES) emerged as the most significant determinant, with individuals from deprived areas experiencing greater barriers to screening, urgent referrals, and treatment access, leading to poorer patient outcomes. Ethnic minorities, particularly Black patients, faced disproportionate reductions in hospital admissions and cancer screening participation. Age-related disparities were also evident, as older adults maintained higher screening rates but faced greater COVID-19 risks, while younger adults from lower-income backgrounds encountered delays in diagnosis and treatment.

The review highlights that the COVID-19 pandemic has exacerbated existing inequalities in UK cancer care, with SES, ethnicity, and age emerging as key determinants. Targeted interventions are essential, including the establishment of COVID-free “cold sites”, deployment of mobile screening units, and culturally tailored outreach programmes for ethnic minority communities. Strengthening regional healthcare capacity and conducting longitudinal assessments will be crucial in addressing disparities and ensuring equitable cancer care. Future research should focus on the long-term consequences of these disruptions on cancer outcomes and healthcare resilience.

The protocol for this systematic review was registered on PROSPERO under the ID CRD42024602280.

The online version contains supplementary material available at 10.1186/s12913-026-14313-8.

## Linked entities

- **Diseases:** cancer (MONDO:0004992), COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** Cancer (MESH:D009369), PICO (MESH:D011248), IMD (MESH:D012892), Oral cancer (MESH:D009062), COVID (MESH:D000086382), Post-COVID (MESH:D000094024), breast cancer (MESH:D001943), YLL (MESH:D003643), infection (MESH:D007239), breast (MESH:D061325), CRC (MESH:D015179), Diabetes (MESH:D003920), HCC (MESH:D006528)
- **Chemicals:** DTT (MESH:D004229), IMD (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** NIHR — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_LB55)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023178/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13023178/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023178/full.md

---
Source: https://tomesphere.com/paper/PMC13023178